| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $203K | -71.1% |
| SG&A Expense | $9.1M | -29.8% |
| Operating Income | -$111.4M | -308.0% |
| Pre-tax Income | -$113.8M | -312.8% |
| Income Tax | $0 | — |
| Net Income | -$149.2M | -441.4% |
| EPS (Basic) | -$38.65 | -439.1% |
| EPS (Diluted) | -$38.65 | -439.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $230K | -97.2% |
| Accounts Receivable | $856K | -29.7% |
| Current Assets | $11.3M | -2.5% |
| Total Assets | $34.1M | -81.8% |
| Current Liabilities | $16.2M | +11.2% |
| Long-term Debt | $3.3M | -61.9% |
| Total Liabilities | $18.2M | -19.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.9M | +42.8% |
| Capital Expenditures | $2.9M | -95.7% |
| Investing Cash Flow | $7.6M | +111.0% |
| Financing Cash Flow | -$2.7M | -763.5% |
| Free Cash Flow | -$16.8M | +82.0% |
| Stockholders' Equity |
| $15.8M |
| -90.4% |